You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Dapagliflozin; metformin hydrochloride - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for dapagliflozin; metformin hydrochloride and what is the scope of patent protection?

Dapagliflozin; metformin hydrochloride is the generic ingredient in two branded drugs marketed by Astrazeneca Ab and is included in two NDAs. There are eleven patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Dapagliflozin; metformin hydrochloride has two hundred and thirty-six patent family members in forty-six countries.

Two suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for dapagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for dapagliflozin; metformin hydrochloride
Generic Entry Date for dapagliflozin; metformin hydrochloride*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET, EXTENDED RELEASE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for dapagliflozin; metformin hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Eli Lilly and CompanyPhase 3
Institute of Liver and Biliary Sciences, IndiaN/A
Ain Shams UniversityPhase 1/Phase 2

See all dapagliflozin; metformin hydrochloride clinical trials

Generic filers with tentative approvals for DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Applicant Application No. Strength Dosage Form
⤷  Subscribe⤷  Subscribe2.5MG;1GMTABLET, EXTENDED RELEASE;ORAL
⤷  Subscribe⤷  Subscribe10MG;1GMTABLET, EXTENDED RELEASE;ORAL
⤷  Subscribe⤷  Subscribe10MG;500MGTABLET, EXTENDED RELEASE;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for dapagliflozin; metformin hydrochloride
Paragraph IV (Patent) Challenges for DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
XIGDUO XR Extended-release Tablets dapagliflozin; metformin hydrochloride 2.5 mg/1000 mg 205649 1 2018-10-29
XIGDUO XR Extended-release Tablets dapagliflozin; metformin hydrochloride 5 mg/500 mg 5 mg/1000 mg 10 mg/500 mg 10 mg/1000 mg 205649 10 2018-01-08

US Patents and Regulatory Information for dapagliflozin; metformin hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Ab XIGDUO XR dapagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205649-001 Oct 29, 2014 RX Yes No ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Astrazeneca Ab XIGDUO XR dapagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205649-002 Oct 29, 2014 RX Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Astrazeneca Ab XIGDUO XR dapagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205649-005 Jul 28, 2017 RX Yes No ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for dapagliflozin; metformin hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca Ab XIGDUO XR dapagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205649-001 Oct 29, 2014 ⤷  Subscribe ⤷  Subscribe
Astrazeneca Ab XIGDUO XR dapagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205649-002 Oct 29, 2014 ⤷  Subscribe ⤷  Subscribe
Astrazeneca Ab XIGDUO XR dapagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205649-001 Oct 29, 2014 ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for dapagliflozin; metformin hydrochloride

Country Patent Number Title Estimated Expiration
New Zealand 574346 CRYSTALLINE SOLVATES AND COMPLEXES OF (IS) -1, 5-ANHYDRO-L-C- (3- ( (PHENYL) METHYL) PHENYL) -D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES ⤷  Subscribe
World Intellectual Property Organization (WIPO) 2011060256 ⤷  Subscribe
Canada 2780939 FORMULATIONS DE COMPRIME BICOUCHE (BILAYER TABLET FORMULATIONS) ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for dapagliflozin; metformin hydrochloride

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1506211 PA2014026 Lithuania ⤷  Subscribe PRODUCT NAME: DAPAGLIFOZINUM + METFORMINUM; REGISTRATION NO/DATE: EU/1/13/900 20140116
1506211 PA 2013 008, C 1506211 Lithuania ⤷  Subscribe PRODUCT NAME: DAPAGLIFLOZINUM; REGISTRATION NO/DATE: EU/1/12/795/001 - EU/1/12/795/010 20121112
1506211 C20130006 00074 Estonia ⤷  Subscribe PRODUCT NAME: DAPAGLIFLOZIN;REG NO/DATE: K(2012)8378 12.11.2012
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Dapagliflozin; metformin hydrochloride Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Dapagliflozin and Metformin Hydrochloride

Introduction

The pharmaceutical market for diabetes treatments is rapidly evolving, driven by increasing cases of diabetes, advancements in medical technology, and changing patient needs. Two key drugs in this landscape are dapagliflozin and metformin hydrochloride. This article delves into the market dynamics and financial trajectory of these medications, highlighting their current status, future prospects, and the factors influencing their market performance.

Increasing Prevalence of Diabetes

The global rise in diabetes cases is a significant driver for the market growth of both dapagliflozin and metformin hydrochloride. The increasing prevalence of type 2 diabetes, fueled by unhealthy lifestyles, genetic mutations, and an aging population, creates a substantial demand for effective diabetes treatments[1].

Market Drivers for Dapagliflozin

Cost-Effectiveness

Dapagliflozin, an SGLT2 inhibitor, has been shown to be cost-effective compared to other glucose-lowering therapies. Studies have indicated that dapagliflozin is cost-saving when compared to GLP-1RAs and DPP-4is, and cost-effective compared to SUs and TZDs in the US setting over a one-year period. This cost-effectiveness is a major driver for its adoption[2].

Clinical Benefits

Dapagliflozin offers several clinical benefits, including improved glycemic control, weight loss, and reduced systolic blood pressure. These benefits contribute to its attractiveness as a treatment option for type 2 diabetes patients[2].

Regulatory Approvals

Dapagliflozin, often combined with metformin in formulations like Xigduo, has received regulatory approvals in various regions, including the European Union. This combination is indicated for adults with type 2 diabetes as an adjunct to diet and exercise to improve glycemic control[5].

Market Drivers for Metformin Hydrochloride

Established Market Presence

Metformin hydrochloride is a well-established first-line treatment for type 2 diabetes. Its long history of use and widespread acceptance make it a staple in diabetes management. The increase in diabetes awareness campaigns and government funding for diabetes treatment further boost its market[1].

High Demand

The lifelong need for diabetes treatment and the growing number of diabetic patients globally drive the demand for metformin hydrochloride. Additionally, the rise in healthcare expenditures and the dependency on metformin hydrochloride for managing type 2 diabetes contribute to its market growth[1].

Market Trends

New Product Launches

The market for both dapagliflozin and metformin hydrochloride is influenced by new product launches and the development of novel diabetes drugs. These innovations often lead to improved treatment outcomes and increased patient compliance, thereby driving market growth[1].

Combination Therapies

The trend towards combination therapies, such as dapagliflozin plus metformin, is gaining traction. These combinations offer enhanced efficacy and better patient outcomes, which in turn drive market demand[5].

Financial Trajectory

Cost-Effectiveness Analysis

Studies have shown that dapagliflozin, despite being more expensive than metformin in some contexts, offers long-term cost-effectiveness. For instance, in China, dapagliflozin treatment was found to be more cost-effective than metformin, with an incremental cost-effectiveness ratio of 10,729 yuan per QALY gained[3].

Market Size and Growth

The metformin hydrochloride market is expected to grow significantly due to the increasing cases of diabetes and the rising demand for type 2 diabetes treatments. The COVID-19 pandemic has also accelerated the growth of the pharmaceutical industry, including the market for diabetes medications, due to increased healthcare expenditures and the need for effective treatments[1].

Challenges and Restraints

Side Effects and Substitutes

Both dapagliflozin and metformin hydrochloride face challenges related to side effects. For example, metformin hydrochloride can lead to gastrointestinal symptoms and rare cases of vitamin B12 deficiency. Dapagliflozin is associated with increased blood creatinine, urinary tract infections, and hypovolaemia. The availability of substitutes, such as homeopathic treatments, also poses a restraint to market growth[1][5].

Opportunities in Emerging Markets

Emerging markets present significant opportunities for the expansion of both dapagliflozin and metformin hydrochloride. The growing healthcare infrastructure and increasing awareness of diabetes in these regions are expected to drive market growth in the future[1].

Competitive Landscape

The competitive landscape for these drugs is intense, with several pharmaceutical companies investing in R&D to improve the quality and efficacy of diabetes treatments. Porter’s five forces analysis highlights the potency of buyers and suppliers in the market, indicating a competitive environment where companies must innovate to stay ahead[1].

Regulatory and Safety Profile

Regulatory approvals and a favorable safety profile are crucial for the market success of these drugs. Dapagliflozin, for instance, has shown a similar incidence of adverse events compared to placebo in clinical trials, making it a safe option for patients[5].

Conclusion

The market dynamics for dapagliflozin and metformin hydrochloride are driven by a combination of factors including increasing diabetes prevalence, cost-effectiveness, clinical benefits, and regulatory approvals. While challenges such as side effects and substitutes exist, the overall financial trajectory for these drugs is positive, with significant growth opportunities in emerging markets.

Key Takeaways

  • Increasing diabetes prevalence drives demand for both dapagliflozin and metformin hydrochloride.
  • Dapagliflozin is cost-effective compared to other glucose-lowering therapies.
  • Combination therapies like dapagliflozin plus metformin are gaining traction.
  • Emerging markets offer significant growth opportunities.
  • Side effects and substitutes are key restraints to market growth.

FAQs

Q: What are the primary drivers for the growth of the metformin hydrochloride market? A: The primary drivers include the increase in cases of diabetes, adaptation of unhealthy lifestyles, rise in population suffering from malnutrition and genetic mutations, and increased healthcare expenditures[1].

Q: How does dapagliflozin compare to other glucose-lowering therapies in terms of cost-effectiveness? A: Dapagliflozin is cost-saving compared to GLP-1RAs and DPP-4is, and cost-effective compared to SUs and TZDs over a one-year period in the US setting[2].

Q: What are the common side effects associated with dapagliflozin? A: Common side effects include increased blood creatinine, urinary tract infections, hypovolaemia, and hypotension[5].

Q: How does the combination of dapagliflozin and metformin benefit patients? A: The combination offers improved glycemic control, weight loss, and reduced systolic blood pressure, making it an effective treatment option for type 2 diabetes patients[5].

Q: What role do emerging markets play in the growth of the dapagliflozin and metformin hydrochloride markets? A: Emerging markets present significant opportunities due to growing healthcare infrastructure and increasing awareness of diabetes, driving future market growth[1].

Sources

  1. Allied Market Research: Metformin Hydrochloride Market Size | Industry Growth By, (2021)
  2. PubMed: Comparison of costs and outcomes of dapagliflozin with other treatments for type 2 diabetes
  3. PubMed: Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in China
  4. Archivepp: RP-HPLC Method for Dapagliflozin and Metformin HCL in Bulk and Combined Formulation
  5. European Union: Xigduo, INN-dapagliflozin/metformin

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.